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Key points 28 
 The neurodegenerative disorders (NDDs) are characterized by protein and other pathologies which can 29 
be reflected in biofluids.  30 
 The use of cerebrospinal fluid (CSF) analysis and molecular imaging has been critical in stratifying 31 
populations based on diagnosis and underlying pathology, but are limited as population screening tools. 32 
 Advances in ultra-sensitive immunoassay measurement of amyloid-β, neurofilament light and tau, as 33 
well as mass spectrometry-based methods for amyloid, have demonstrated that a blood-based screening 34 
tool for Alzheimer’s disease (AD) is a realistic and plausible possibility.  35 
 This evidence is now indicating that such blood biomarkers could be important for other common NDDs 36 
(e.g, LBD & FTD). 37 
 38 
Word count: 6,660 (including in-text references) 39 












In recent years, there has been an increasing emphasis on the importance of blood-based biomarkers in the first-52 
in-line evaluation of patients with suspected neurodegenerative disorders (NDDs). While neuroimaging (structural 53 
and molecular) and cerebrospinal fluid (CSF) analyses identify the underlying pathophysiology at the earliest 54 
stage, a biologically relevant marker derived from blood would have greater utility in the primary care setting and 55 
in the early eligibility screening for therapeutic trials. The rapid advancement of ultra-sensitive assays has enabled 56 
the investigation of pathological proteins to be measured in blood samples, but research has been predominately 57 
focused on Alzheimer’s disease (AD). Nonetheless, proteins that are currently under scrutiny as blood biomarker 58 
candidates for AD (amyloid-β, tau and neurofilament light chain) are likely to have fundamental importance for 59 
Lewy body dementia’s (LBD), frontotemporal dementia (FTD) and other NDDs in terms of shared pathologies, 60 
similar degenerative processes or in the differential diagnosis of clinical symptoms. This review gives an overview 61 
and update on the current status of blood-based biomarkers for the non-AD NDDs, focusing on how candidate 62 
AD and novel protein, metabolomic and RNA biomarkers perform in these populations. As background 63 
information, we also briefly outline the neuropathological, clinical, molecular imaging and CSF features of the 64 
most common NDDs outside of the AD continuum.   65 
 66 
Introduction 67 
Age-related cognitive disorders represent a major and escalating societal challenge due to the growing number of 68 
elderly people. Many failed anti-dementia trials have been published, and one potential reason is a lack of synergy 69 
between drug and disease mechanisms. Precision medicine, i.e. characterization of the individual’s phenotype and 70 
genotype for stratifying the right patient to the appropriate therapy, is therefore fundamentally important. To 71 
achieve this, accurate, minimally invasive, safe, and inexpensive biomarkers are needed that can be broadly 72 
administered to communities worldwide. 73 
The foremost neurodegenerative disorders (NDDs) are characterized by aggregates of abnormal proteins found in 74 
the central nervous system (CNS), which allows for a mechanism-based proteomic biomarker search. Six hallmark 75 
proteins enable the classification of most NDDs: two of them are extracellular, amyloid-β (Aβ) and the prion 76 
protein (PrPsc), four are intracellular: tau, alpha-synuclein (α-synuclein), TAR DNA-binding protein 43 (TDP-77 
43) and fused in sarcoma (FUS)1, leading to amyloidopathies, prionopathies, tauopathies, α- synucleinopathies, 78 
TDP43-proteinopathies, respectively. The neurodegenerative pathologies often coexist and additional vascular 79 
changes are also prevalent causing clinical and neuropathological heterogeneity1. The numerous triplet disease 80 
disorders (spinocerebellar ataxias, Huntington’s disease) are not included in this list, because they form, to some 81 
extent, a separate group of genetically defined movement disorders.  82 
The presenting clinical manifestations and syndromes vary between NDDs but are related to the severity, type, 83 
and regional distribution of the proteinopathies (Table 1). Whereas AD is typically characterized by memory 84 
impairment, aphasia, apraxia, and agnosia, related to the involvement of medial temporal lobe and parietal cortex, 85 
the frontotemporal dementias (FTDs) are characterized by behavioral and language changes, and Lewy body 86 
dementias (Parkinson disease dementia (PDD) and dementia with Lewy Bodies (DLB)) by executive, attentional, 87 
and visuospatial impairment and non-cognitive symptoms such as parkinsonism, REM-sleep behaviour disorder, 88 
autonomic symptoms and visual hallucinations. The neuroanatomical distribution of proteinopathy pathology help 89 
to establish consensus protocols for neuropathological assessment and diagnosis1. The clinico-pathological 90 
correlation is however difficult to establish. In addition, most NDDs are heterogeneous diseases, i.e. combinations 91 
of proteinopathies, thus biomarkers, such as imaging and proteomic analysis, are crucial for accurate diagnosis 92 
which may allow detection in early prodromal or even pre-clinical stages for early interventions when available. 93 
With the exception of AD, where the most recent diagnostic criteria2-5 and research framework6 include 94 
biomarkers to establish the typical proteinopathy, non-AD NDDs are diagnosed by clinical features, although 95 
biomarkers can aid in the identification process. 96 
Structural Magnetic Resonance Imaging (MRI) provides regional measures of brain atrophy, reflective of 97 
neurodegenerative processes, including dendritic pruning, synaptic loss and neuronal depletion. As dementia 98 
disorders are associated with spatially distinct patterns of regional volume loss7, MRI based markers of atrophy 99 
are included in certain diagnostic criteria for non-AD NDDs8-10. The introduction of in vivo positron emission 100 
tomography (PET) brain imaging has had a transformative impact in the context of NDDs, helping to both refine 101 
disease progression models and serve as a powerful diagnostic aid, complementing clinical and cognitive 102 
evaluations. Beginning with metabolic imaging using 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG), supposedly 103 
reflective of neuronal or synaptic integrity11, the field next saw the introduction of, amongst many others, ligands 104 
capable of mapping and quantifying fibrillar Aβ12 and more recently, ligands specific for paired-helical filament 105 
(PHF) tau13,14 and synaptic density15. 106 
The clearance of abnormal proteins via the cerebrospinal fluid (CSF) is an endogenous neuroprotective 107 
mechanism of the brain. Not only for extracellular Aβ, but also intracellular and synaptic proteins can leak into 108 
the CSF, and their reductions or accumulation can be used as a disease or disease progression biomarkers. 109 
However, a blood-based measure of such pathologies has substantial practical and economic advantages over 110 
imaging and CSF biomarkers currently utilized in clinical and research settings. Molecular imaging is costly, and 111 
access is limited to specialised centres. CSF analysis is more affordable and attainable but there remains a 112 
perceived invasiveness attached to a lumbar puncture, which may limit its use in clinical practice, depending on 113 
the healthcare system. Therefore, a blood-based marker would be of extreme value as a simplified initial triage 114 
step in a multi-stage assessment for cognitive complaints, secondary prevention trial selection or monitoring 115 
response to intervention. 116 
In AD, there are already excellent imaging (FIG.1.)16, CSF (Table 2)17 and promising blood biomarkers being 117 
developed (Table 2)18. In contrast, fluid biomarkers in non-AD NDDs remain in their infancy but will greatly 118 
benefit from the findings in AD studies. In this review, as background, we first briefly summarize clinical and 119 
neuropathological features of the most common non-AD NDDs and discuss the main findings from imaging and 120 
CSF studies. The focus is on the developing topic of blood-based biomarkers in key non-AD NDDs, such as LBD 121 
or FTD. After briefly reviewing the lessons from AD, we will discuss how this can inform our understanding of 122 
non-AD NDDs and consider disease specific biomarkers in these other neurodegenerative conditions. 123 
 124 
Neuropathological, clinical and imaging overview of non-Alzheimer NDDs 125 
Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy Bodies 126 
Parkinson’s disease (PD) is the second most common neurodegenerative disease (exceeded only by AD) and is 127 
characterized by the accumulation of α-synuclein in inclusions known as Lewy bodies and Lewy neurites. The 128 
frequency of PD increases with aging (the mean age of onset of approximately 60 years) and the lifetime risk is 129 
slightly higher for men than for women. Although most cases are sporadic, some rare cases are familial. The 130 
pathological hallmark is the progressive loss of nigrostriatal dopaminergic neurons of the substantia nigra pars 131 
compacta. As a result of this dopaminergic pathology, PD typically manifests with a parkinsonian syndrome or 132 
parkinsonism, which is defined by the combination of the following motor clinical features: rest tremor, rigidity, 133 
bradykinesia and gait dysfunction with postural instability19. Of note, PD is the most common cause of 134 
parkinsonism but not the only one. Other neurodegenerative disease (e.g. progressive supranuclear palsy (PSP), 135 
cortical basal degeneration (CBD) or FTD) or secondary causes (e.g. metabolic, toxic, drug-induced, and vascular) 136 
can also lead to a parkinsonism. Besides the motor clinical features, PD also manifests with non-motor features, 137 
including hyposmia, sleep disorders, autonomic dysfunctions, pain, behavioural disturbances and cognitive 138 
impairments. Remarkably, a considerable number of patients with PD will eventually develop cognitive 139 
impairment and dementia over the course of their illness, a condition termed Parkinson’s disease with dementia 140 
(PDD)20,21. Yet, the timing of the onset of dementia is highly variable and some patients rapidly develop dementia 141 
while others display no signs of cognitive impairment for many years and in some cases never develop 142 
dementia22,23. In patients where dementia precedes or arises concomitantly with the motor clinical features, the 143 
patient is diagnosed as dementia with Lewy bodies (DLB)24. Together, PD, PDD and DLB constitute the Lewy 144 
body diseases and a considerable clinical and pathological overlap exist between them. In particular, PDD and 145 
DLB are distinguished solely based on the relative timing of parkinsonism and dementia, i.e. if dementia occurs 146 
more than one year after the diagnosis of PD, the clinical diagnosis is PDD; whereas patients where dementia 147 
occurs before or simultaneously with parkinsonism are diagnosed as DLB. This distinction is arbitrary, and many 148 
patients are difficult to classify because the timing of cognitive decline and parkinsonism can be difficult to 149 
establish. The cognitive profile of Lewy body diseases varies but differs from that in AD in that it is characterized 150 
by relatively more executive, attentional and visuospatial impairment, although memory is usually impaired and 151 
often the first reported symptom. Interestingly, there are lesions outside the brain, with involvement of the 152 
autonomic nervous system leading to characteristic symptoms such as orthostatic hypotension and constipation. 153 
Among the neuropsychiatric symptoms, visual hallucinations and REM-sleep behavior disorder (RBD) are typical 154 
of Lewy body diseases. 155 
In addition to the Lewy body and α-synuclein pathology, DLB and PDD often show varying degrees of AD co-156 
pathology22. The clinicopathologic correlation with the extent and severity of α-synuclein pathology is often 157 
blurred by the co-existing AD pathology, which has to be considered when the degree of probability is established 158 
regarding α-synuclein being the cause of clinical symptoms9. Less frequently, concomitant TDP-43 pathology is 159 
detectable25.  160 
Beyond the exclusion of secondary causes of parkinsonism— such as vascular, demyelinating or space-occupying 161 
lesions within the brainstem or basal ganglia—conventional T1- and T2-weighted MRI sequences are considered 162 
of limited use in the diagnosis of PD as visual reads are often normal26,27. The degree and regional distribution of 163 
volumetric loss is variable in DLB, but absent or minimal atrophy of the medial temporal lobe has been identified 164 
as a consistent feature9. Recent advances in MRI methodology, including iron‐sensitive techniques such as 165 
susceptibility‐weighted imaging and quantitative susceptibility mapping, show promise in capturing abnormalities 166 
within the substantia nigra and nigrostriatal system28. Using [18F]FDG PET, a pattern of temporoparietooccipital 167 
hypometabolism is typically observed in DLB and PD/PDD29-32, with the latter additionally showing relative 168 
hypermetabolism in the motor cortex, striatum, thalamus and cerebellum33. In keeping with the degeneration of 169 
nigrostriatal dopamine neurons as a defining feature of DLB and PD/PDD, dopaminergic function, whether 170 
measured by SPECT or PET, is markedly decreased in both34,35. Using amyloid-β imaging, retention levels have 171 
been shown to be low in PD patients, somewhat increased in PDD and elevated in DLB36-39 and to associate with 172 
cognitive decline37,38,40. In DLB and PD/PDD, early tau PET findings have varied, yielding rather inconsistent 173 
results between studies, with cortical ligand binding overlapping with controls41-43. [18F]Flortaucipir—and, 174 
possibly, related newer tau compounds44—has been shown to bind to neuromelanin in the substantia nigra45,46. As 175 
such, tau PET may be of use in PD/PDD due the characteristic loss neuromelanin rich neurons in this region. 176 
Overall, is not yet clear how tau pathology contributes to the development of these disorders47,48. 177 
 178 
Frontotemporal Dementia (FTD) 179 
FTD is a clinically and pathologically heterogeneous group of NDDs that predominantly exhibit frontal and/or 180 
temporal involvement. There are two main clinical presentations of FTD: the behavioural variant (bvFTD), which 181 
mainly leads to personality alterations and behavioral problems, and the less common primary progressive 182 
aphasias (PPA), which cause progressive deterioration of speech and/or language49, and which can be further 183 
subtyped into semantic (svPPA), non-fluent (nfvPPA). The third subtype of PPA, the logopenic variant (lvPPA), 184 
is usually associated with classical AD pathology. The international consensus criteria50 defines possible bvFTD 185 
by the persistence or recurrence of at least three of the following symptoms, (i) early behavioural disinhibition, 186 
(ii) apathy, (iii) loss of empathy, (iv) perseverative, stereotyped, compulsive or ritualistic behaviours, (v) 187 
hyperorality and dietary changes, (vi) executive deficits9 with relative preservation of memory and visuospatial 188 
functions, and by  progressive deterioration of behaviour and/or cognition50. Finally, it is worth mentioning that 189 
familial FTD is observed in approximately a third of all FTD cases49. The most commons genes involved in FTD 190 
are MAPT, GRN and C9orf72. A probable FTD diagnosis is made, when a suspected clinical FTD is accompanied 191 
by either a causative genetic mutation or neuroimaging evidence of disproportionate involvement of frontal and/or 192 
temporal lobes51. Because of their clinical heterogeneity, and the lack of reliable peripheral biomarkers, FTD 193 
continues to pose major diagnostic challenges in clinical settings52. 194 
While the term FTD is usually applied to the clinical syndromes, the term ‘frontotemporal lobar degeneration’ 195 
(FTLD) is the neuropathological term. Three hallmark proteins define the FTLD pathological subtypes: (1) TDP-196 
43, (2) Tau or (3) FET proteins (FUS, EWS and TAF-15). Consequently, FTLD are pathologically classified in 197 
FTLD-TDP, FTLD-tau and FTLD-FET53. FTD may overlap clinically and pathologically with motor neuron 198 
disease (MND) or some extrapyramidal syndromes (cortical basal syndrome, CBS or PSP). In fact, the most 199 
common underlying pathology in MND (and, in particular, in amyotrophic lateral sclerosis (ALS), the most 200 
prevalent MND) is also TDP-43 pathology. Some ALS cases are caused by mutations in C9orf72, FUS (i.e. ALS-201 
FUS)54,55 and have inclusions of demethylated FUS56,57. Likewise, the underlying pathology in corticobasal 202 
degeneration (CBD) and PSP is deposits of tau in astrocytes. 203 
In bvFTD, MRI studies demonstrate prominent, usually symmetric, atrophy of the frontal lobes8. In contrast to 204 
the pattern typically seen in AD, involving the posterior temporal/parietal lobes and the posterior 205 
cingulate/precuneus58-62, three main patterns of glucose hypometabolism can classically be observed in FTD: 206 
precentral and inferior frontal in nfvPPA, anterior temporal lobes in svPPA (usually with marked leftward 207 
asymmetry)63,64, and frontal as well as temporo-limbic predominant patterns in bvFTD65. In case series that have 208 
examined Aβ status among FTD patients, low rates of Aβ positivity have been reported (0-15%), in line with Aβ 209 
plaques not being a feature characteristic of the FTLD pathology spectrum66-68. In patients across FTD syndromes, 210 
a recent study found low-level elevated tau-PET binding in disease-typical regions in individuals suffering from 211 
nfPPA (inferior frontal areas), CBS (precentral gyrus and frontal white matter in a subset of cases), and bvFTD 212 
(fronto-temporal regions)69,70. Yet, autoradiography studies have suggested that existing tau-PET tracers do not 213 
bind to tau isoforms underlying non-AD tauopathies71-73, urging for a cautious interpretation of the in vivo PET 214 
findings. Molecular (Aβ, tau) and functional (glucose metabolism) PET scans for an illustrative case of bvFTD—215 




Cerebrospinal fluid (CSF) biomarkers of non-Alzheimer’s NDDs 220 
The core CSF biomarkers for AD (Aβ42, T-tau and P-tau), reflecting the defining Aβ and tau pathologies,   221 
consistently demonstrate diagnostically significant changes across studies74 and now have prominent positions in 222 
the research diagnostic criteria for AD5,6. One way of refining Aβ pathology biomarkers is to combine Aβ42 and 223 
Aβ40 in a ratio. This ratio has repeatedly been shown to be a more reliable biomarker for cerebral Aβ pathology 224 
than CSF Aβ42 alone, most likely by normalizing for inter-individual differences in amyloidogenic APP-225 
processing 75. The concentrations of these core AD biomarkers are largely normal in the majority of dementias 226 
outside of AD76,77. This can be of great utility in the differential diagnosis of patients with cognitive symptoms. 227 
However, there are isolated exceptions to this rule; Aβ42 is abnormally decreased in half of DLB cases and many 228 
PDD patients78,79 which highlights the overlapping pathologies with AD. Furthermore, marked increases of T-tau 229 
in Creutzfeldt-Jakob disease (CJD)80 is a common observation whereas the concentrations P-tau remain normal 230 
or only marginally changed in CJD81. An unpredicted finding is that levels of CSF tau are largely normal in FTD. 231 
This includes concentrations of total tau and specific phosphorylated epitopes (P-tau181, P-tau231 and P-232 
tau199)77,82,83 and N-terminal tau fragments truncated at 224 (tau6-224 or x-224)84. The same holds true for other 233 
primary tauopathies (e.g. PSP)85,86. The reason for this remains unclear but may suggest lower secretion of tau 234 
proteins to the extracellular space and the CSF, or alternative processing of full-length tau that are not captured 235 
by the commonly used mid-domain immunological assays. 236 
Neurofilament light chain (NFL) is the smallest of the neurofilament triplet proteins that are the structural 237 
components of the axons. NFL is released from the axons in normal ageing, however, in response to axonal 238 
damage (via neurodegeneration, inflammation, vascular or traumatic), NFL released is accelerated into the 239 
extracellular space where its concentration increases in the CSF. Several studies have shown that CSF NFL levels 240 
are high in brain disorders with subcortical pathology, such as vascular dementia (VaD) and normal pressure 241 
hydrocephalus87,88. Notably, CSF NFL concentrations are clearly higher in FTD than in AD with onset of a similar 242 
age89, which supports that NFL aids in this differential diagnostic specific situation. In addition, CSF NFL also 243 
shows a very marked increase in CJD (correlating with CSF T-tau)90, due to the very extreme level of 244 
neurodegeneration. Importantly, while CSF NFL is relatively normal in pure PD, several studies have shown a 245 
very marked increase in CSF NFL in atypical parkinsonian disorders (APD), specifically in CBS, multiple 246 
systemic atrophy (MSA), and PSP85,91,92.  247 
Measurements of total monomeric α-synuclein in CSF has been proposed as a biomarker for PD and DLB, but 248 
most studies only show minor reductions in PD, with considerable overlap between controls and other patient 249 
groups93. A meta-analysis that included >3000 subjects across 17 studies also reported significantly lower levels 250 
of CSF α-synuclein in PD but concluded that α-synuclein is not yet helpful in diagnosis of PD or DLB94. This 251 
observation might be explained by two reasons: (1) α-synuclein is present in 10,000-fold higher in blood, 252 
suggesting that CSF contamination may introduce peripheral α-synuclein not related to neurodegeneration, and 253 
(2) that α-synuclein levels might be linked to two “pathologies” e.g. α-synuclein inclusion pathology but 254 
simultaneous leakage to the CSF as a consequence of neurodegeneration. Hence, identification of a brain-specific 255 
pathological forms of α-synuclein is crucial to advancing disease-specific biomarkers. Recent developments allow 256 
for the assessment of the pathological forms of α-synuclein in CSF using the real-time quaking-induced 257 
conversion (RT-QuIC) technology. This diagnostic platform explores the self-replicating property of 258 
proteinopathic proteins, with sensitivity and specificity figures for PD and DLB exceeding 90%95,96. Importantly, 259 
new variants of α-synuclein RT-QuIC assays can be performed more rapidly, within 1-2 days95, supporting their 260 
use as a diagnostic tool for synucleinopathies and also prionopathies97. 261 
High CSF levels of the postsynaptic protein neurogranin have repeatedly been found in AD98-101. A recent study 262 
confirmed that this marked increase is seemingly specific to AD, while normal concentrations were found in a 263 
wide range of other NDDs, including FTD and DLB102 but contradictory reports for PD102,103. Similar finding has 264 
been reported for presynaptic protein growth-associated protein 43 (GAP-43)104. Thus, CSF neurogranin and 265 
GAP-43 may be the latest addition in the toolbox to differentiate AD from non-AD NDDs. 266 
 267 
Introduction to blood biomarkers in neurodegenerative research: challenges and technologies 268 
Although easily accessible, the complexity of analysing blood content (plasma or serum) must not be 269 
underestimated. Firstly, due to its continuous and uninhibited exchange with the brain, truly brain-derived 270 
molecules will be considerably higher in concentration in the CSF for the same analyte in blood. Blood 271 
communicates with the brain across the blood brain barrier (BBB), via lymph vessels and through the glymphatic 272 
system105 and on entering the bloodstream, a brain-derived analyte will be diluted in a complex matrix of highly 273 
abundant plasma proteins (e.g. albumin, IgG, transferrin, haptoglobin, and fibrinogen) that span >10 orders of 274 
magnitude. These “matrix effects” can have a large and inconsistent impact on the ability of an immunoassay to 275 
accurately quantify a specific target and can result in misleading conclusions. Moreover, protein biomarkers may 276 
undergo protease degradation, have substantial peripheral expression including in blood cells such as platelets and 277 
erythrocytes, exist as multiple isoforms or contain stable and/or dynamic post-translational modifications. Lastly, 278 
analytical factors such as interference from heterophilic antibodies or variations in blood collection methods, 279 
processing and storage, can affect analytes in a different manner. All these factors will introduce a high degree of 280 
variability that is unrelated to the disease itself which can be difficult to account for. The choice of analyzing 281 
plasma or serum is also an important aspect to consider. An analyte of potential interest cannot merely be assumed 282 
to correlate well between these blood fractions106. While serum and plasma measures of NFL correlate well, with 283 
serum NFL exhibiting consistently higher concentrations107, it is considered that plasma is the preferred matrix 284 
for Aβ42, Aβ40 and T-tau. 285 
Proteomic approaches for blood biomarker studies can be simplified into two main strategies; targeted and non-286 
targeted, where the latter tends to feed into a more analyte-specific platform (FIG. 2). A common non-targeted 287 
“hypothesis generating” methodology employed in neurodegenerative research is label-free or isobaric liquid 288 
chromatography tandem mass spectrometry (LC-MS/MS), where a protease-digested peptide mixture is typically 289 
ionised and fragmented for identification and quantification simultaneously. For blood analysis, LC-MS/MS 290 
methods are typically complemented with upfront peptide/protein fractionation or the immunodepletion of highly 291 
abundant plasma proteins which vastly improve the level of identification108. LC-MS/MS can also be employed 292 
in a targeted manner if an analyte of interest has been acquired. Selection reaction monitoring (SRM) methods 293 
allows for better precision, more accurate quantification and higher throughput than unbiased LC-MS/MS 294 
methods. Capture-based techniques, that typically involve paired antibodies in the sandwich immunoassay format, 295 
remain the most popular technique for all biomarker analyses.. The combination of antibody capture followed by 296 
mass spectrometry (IP-MS) has been a popular tool for detailed characterization of a target of interest, particularly 297 
in AD biomarker research (e.g Aβ peptides). The fundamental basis for most new generation immunocapture 298 
assay follows the same workflow as a colorimetric enzyme-linked immunoassay (ELISA) format. The emergence 299 
of electrochemiluminescent (ECL) assays has theoretically allowed for the multiplexing of 10 (MesoScale 300 
Discovery, MSD) to 100 (Luminex, xMAP) analytes. However, these assays still experience the typical issues of 301 
antibody-based capture methods (dynamic range variability, specificity and cross-reactivity) that restrict 302 
multiplexing to a much more modest number than initially stated. Therefore, an initial biomarker discovery screen 303 
may not be suited to these strategies but are of tremendous value for the high throughput validation of a specific 304 
target(s) or pathway(s). The next wave in variations of the capture-based methodology includes Proximity 305 
Extension Assay (PEA, Olink), SOMAscan (Somalogic), Single Molecule Counting (SMCxPro), Single 306 
molecular array (Simoa, Quanterix), as well as fully automated immunoassays with electrochemiluminescence 307 
detection, e.g., Elecsys. In the case of blood biomarkers reflecting neurodegeneration, analytical precision of a 308 
single target has far more value than the simultaneous measurements of multiple analytes at the cost sensitivity. 309 
The SMCxPro and Simoa platforms utilise traditional antibody sandwich immunocomplex technology with a sub-310 
femtomolar level of measurement in blood. In both occasions, individual immunocomplexes are isolated utilising 311 
novel microfluidics and the fluorophores are excited allowing for detection of single molecules of the target of 312 
interest. The Simoa or “digital ELISA” is now the preferred tool to measure Aβ, Tau, NFL and Glial fibrillary 313 
acidic protein (GFAp) in blood for acute and chronic neurological injury. 314 
A final and important consideration in the development of a blood-based assay for neurodegenerative dissease is 315 
the intended context of use (COU) and translation from laboratory validation to clinical use. The Alzheimer 316 
Precision Medicine Initiative (APMI) recently published guidelines of a multi-tiered approach to biomarker 317 
evaluation as well as sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) 318 
suggestion depending on the intended COU18.    319 
The current state of blood biomarkers for AD 320 
The search for robust blood biomarkers of AD pathology has now entered a second decade. Until recently, research 321 
on candidate blood biomarkers for AD had predominantly focused on proteins that are expressed at relatively high 322 
concentrations in the blood109-111. During recent years, technological advances in combination with better 323 
characterised clinical cohorts (including neuroimaging and CSF biomarker information on AD pathology) have 324 
led to a number of breakthroughs. The “endophenotype” approach has highlighted promising blood markers 325 
indicative of brain atrophy111,112 and cerebral amyloid pathology113-117. Despite the commonality of these markers 326 
reaching nominal statistical significance across several studies, with supportive genomic and in vitro evidence 327 
(e.g. clusterin), they have not demonstrated the sensitivity and specificity required for clinical notoriety. 328 
Therefore, at this current time, the most promising blood biomarker candidates for AD are markers initially 329 
derived and converted from CSF assays (Table 3).   330 
Aβ peptides can be readily measured in plasma using standard ELISA or ECL assays, but a large number of studies 331 
have historically shown no clear change between clinically diagnosed AD cases and cognitively unimpaired 332 
elderly74. However, this opinion is now being challenged as recent mass spectrometric118-120, Simoa121 and fully 333 
automated immunoassays122 have provided evidence to suggest that Aβ peptide ratios can identify brain Aβ-334 
positive individuals with high sensitivity and specificity. The assessment of plasma T-tau in AD has been 335 
conducted in large research cohorts, with significant increases observed in AD123,124. However, the substantial 336 
overlaps between control groups, and poor correlations with CSF levels certainly limits plasma T-tau as being 337 
diagnostically useful123. Nonetheless, plasma T-tau may improve the prediction of future dementia. A prospective 338 
study performed in the Framingham Heart Study demonstrated that higher concentrations of plasma T-tau resulted 339 
in a 35% higher risk for AD dementia when adjusted for age and sex124. In regards to P-tau, a semi-sensitive assay 340 
for P-tau181 (similar to the most employed CSF test) with ECL detection has been developed125. Using this assay, 341 
plasma P-tau concentrations are higher in AD dementia patients than controls. Using the same platform, data from 342 
two independent studies were recently presented at the Alzheimer’s Association International Conference® (2019) 343 
In both studies, P-tau correlated tightly with [18F]flortaucipir in Aβ-positive cases, CSF P-tau181 and a step-wise 344 
increase of P-tau was observed with Braak Staging signifying that blood P-tau could be a very early indicator of 345 
AD pathology. Further, a study using an immunomagnetic reduction (IMR) assay for plasma P-tau181 found a very 346 
clear increase in MCI-AD and AD dementia with area under curve (AUC) values of 0.79 and 0.84, respectively126. 347 
Although not disease specific, blood NFL has potential as a marker to identify or rule out neurodegeneration since 348 
NFL is consistently increased in AD127-129, prodromal AD127 and familial AD130,131. Further observations within 349 
AD cohorts also show that blood NFL correlates with cognition127,128, CSF biomarkers, post-mortem pathology132 350 
and structural imaging modalities127. Interestingly, blood NFL can predict AD onset in patients with Down’s 351 
syndrome133,134. The promising progress in CSF biomarkers for synaptic integrity in AD, e.g. neurogranin, has yet 352 
to translate to blood. Plasma concentrations of neurogranin are detectable by conventional ELISAs but are 353 
unchanged in AD with no correlation with CSF neurogranin, probably due to the contribution of peripherally 354 
expressed neurogranin peptides135,136. As new CSF assays for synaptic integrity emerge (i.e GAP-43)137 and 355 
technology continues to advance, the hope for a synapse specific marker in blood still remains.    356 
 357 
Blood biomarkers in non-Alzheimer’s NDDs 358 
As we have previously declared, the vast majority of blood biomarker research in neurodegenerative disorders 359 
has focused on AD and this is principally owing to a larger population pool for biomedical research. As imaging 360 
and CSF biomarkers now guide the accurate classification of AD, blood biomarkers are becoming increasingly 361 
accurate. This enhanced in vivo characterization of pathologies and advances in ultra-sensitive technologies for 362 
blood biomarker detection has and will continue to benefit non-AD NDD’s.  363 
Targeted protein biomarkers for non-AD NDD’s 364 
Amyloid-beta—The lowest plasma Aβ42 concentrations across non-AD NDDs have been reported in patients with 365 
DLB, but the difference did not reach statistical significance compared to other NDDs and no data on the 366 
Aβ42/Aβ40 ratio was provided138. In the same study, it was reported the patients with FTD exhibited Aβ42 367 
concentrations significantly higher than all other groups138, which is a potentially interesting finding given the 368 
low prevalence of Aβ binding in PET studies and subsequent higher concentrations of CSF Aβ42 in FTD studies.  369 
Clearly, more studies are needed on plasma Aβ in non-AD NDDs and whether reduced ratio of Aβ42/Aβ40 in 370 
plasma could be useful to detect Aβ pathology in DLB or exclude AD in non-Aβ-associated NDDs such as FTD 371 
and PSP remains to be examined. However, the peripheral expression of Aβ may confound an ultra-specific 372 
association of plasma Aβ concentrations with cerebral Aβ pathology139. 373 
T-tau—The expression of tau is brain-enriched and is detectable in multiple forms in plasma. However, as with 374 
Aβ, tau has peripheral expression and is detectable at both the mRNA and protein level in salivary glands 140 and 375 
kidney (http://www.proteinatlas.org/ENSG00000186868-MAPT/tissue). This is an important potential 376 
confounder that may explain the poor correlation between plasma tau with CSF tau, as previously seen in studies 377 
in AD141. The half-life of tau also appears to be much shorter (hours) in plasma142 than in CSF (weeks)143, which 378 
could also make it less reliable as a biomarker for neurodegeneration when measured in blood. Nonetheless, 379 
sensitive assays for T-tau have recently been developed on the Simoa and IMR platforms for its sub-femtomolar 380 
detection in plasma. Plasma concentrations of T-tau have diagnostic importance in specific NDDs tauopathies. 381 
Consistent with observations in CSF, patients with CJD, for example, have high levels of T-tau relative to other 382 
rapidly progressive dementias, AD and healthy controls144,145 which positively associates with disease 383 
progression145. But, contrary to findings in CSF, IMR data demonstrates significantly increased plasma T-tau in 384 
patients with a clinical diagnosis of PD, DLB, and APD compared to controls146, with a two-fold further increase 385 
in FTD with parkinsonism (FTD-P) or without parkinsonism138. Moreover, plasma T-tau is increased in bvFTD, 386 
PPA (irrespective of subgroup) and genetic FTD subtypes (C9orf72, MAPT and GRN) compared with controls 387 
when measured with Simoa147. However, the group overlaps are large, which negates diagnostic usefulness on a 388 
case-by-case basis, and there was no significant correlation with cross-sectional or longitudinal brain volume 389 
changes or disease duration147.  390 
Preliminary evidence suggests that the plasma N-terminus tau fragment (amino acids 6-198) is increased in MCI 391 
and AD148. Given that this tau fragment partly overlaps with the species measured by some commercial T-tau 392 
assays, it will be worth studying if tau6-198 has diagnostic or prognostic importance in primary tauopathies as well 393 
as AD.  394 
 395 
P-tau—There have been very few reports measuring plasma P-tau181 concentrations in AD125,126,149 and in non-396 
AD NDDs. By using IMR, P-tau181 was shown to be significantly increased compared to healthy controls in PD, 397 
DLB, CBS, MSA and PSP138 but in combination with plasma Aβ42, P-tau181 concentrations were particularly 398 
prominent in separating FTD patients from PD, DLB and atypical parkinsonian disorders with 88.9% specificity 399 
and 92.9% sensitivity, a promising result in need of replication. In contrast to this, the promising P-tau data 400 
presented at Alzheimer’s Association International Conference® (2019) demonstrated no increases in CBS, PSP 401 
and bvFTD as compared to control participants, suggesting that increases of P-tau in blood is AD specific and 402 
potentially amyloid related. The plasma concentrations of P-tau were able to distinguish AD cases from FTLD 403 
cases with an AUC >0.90 in two independent studies from BioFINDER and the University of California, San 404 
Francisco. 405 
Neurofilaments—A close correlation between NFL concentrations in blood and CSF have been replicated in many 406 
studies spanning a broad range of conditions127,150-155 and therefore many of the reported observations of CSF NFL 407 
have been replicated in blood. While studies on the AD spectrum report correlation coefficients of between 0.5-408 
0.75, rapidly progressing conditions or NDDs that have a larger effect on the blood-brain barrier (e.g. ALS or 409 
HIV-dementia) have far stronger associations. Given these robust relationships, it has been postulated that blood 410 
NFL could replace CSF NFL for the assessment of on-going axonal injury for some NDDs. However, it remains 411 
unclear if blood NFL concentrations change concurrently with CSF without delay or if this correlation remains 412 
strong across a longitudinal trajectory, an important consideration for an early marker of neurodegeneration or 413 
monitoring therapeutic response. Another potential confounder is the degree of peripheral nerve disorders 414 
influencing blood NFL levels156,157. Elevations of NFL are observed in almost all NDD’s but also inflammatory, 415 
traumatic and vascular conditions however blood NFL can be used to distinguish between patients with PD and 416 
APD with high diagnostic accuracy (AUCs 0.81–0.91) which is similar to the diagnostic accuracy of CSF NFL92. 417 
Patients with ALS demonstrate the most marked increases in blood NFL. However, within the spectrum of NDDs, 418 
patients with FTD158,159 and CJD90 approach concentrations levels similar to ALS. The serum concentrations of 419 
phosphorylated neurofilament heavy (pNFH) can also be accurately detected using the Simoa platform160, which 420 
correlate well with CSF pNFH in FTD and ALS patients160-162. This robust association suggests that pNFH 421 
concentrations in peripheral blood, in the same manner to NFL, is a potential peripheral biomarker for neuronal 422 
damage in non-NDD’s. Indeed, pNFH concentrations in serum can separate ALS patients from controls with an 423 
AUC >0.90 and distinguish ALS from FTD with an AUC >0.85160. Sensitive measures of pNFH might be more 424 
robust than NFL163, have a more favorable outcome against preanalytical variables164 and exhibit different release 425 
and/or clearance dynamics160. 426 
Fatty acid-binding proteins (FABPs)—these small intracellular proteins facilitate the transport of fatty acids 427 
between the cell membrane and different organelles. Enriched in neurons, increased CSF FABP has been linked 428 
to axonal neurodegeneration in AD165,166. Furthermore, reductions in heart-type FABP have been reported in brain 429 
tissue from patients with Down's syndrome and AD167. In serum, increases of FABP have been reported in AD168 430 
but also marked increases in CJD169, DLB168,170-172 and PD172. 431 
α-synuclein—Levels of total, oligomeric, and phosphorylated α-synuclein in peripheral tissues and body fluids of 432 
people with PD have been extensively evaluated173. Most studies investigating α-synuclein have used CSF, but 433 
findings have been disappointing. As mentioned previously, the contamination of blood during lumbar puncture, 434 
due to very high concentration of α-synuclein in red blood cells, is a major potential confounder affecting these 435 
studies. It is therefore unsurprising that measuring total α-synuclein174-176 in the plasma of PD patients has yielded 436 
inconsistent results. However, increases in oligomeric α-synuclein in serum177 and red blood cells178-180 have been 437 
shown in PD patients with moderate diagnostic performance. Further, increases in phosphorylated forms of α-438 
synuclein in plasma174 and a panel of post-translational modifications on α-synuclein (e.g., Tyr125 439 
phosphorylation and glycosylation) have demonstrated modest discriminatory power, AUC 0.71 and 0.84 440 
respectively181. More recently, Lin et al182 demonstrated that plasma total α-synuclein (with IMR) levels are 441 
significantly higher in people with PD compared with control subjects, and particularly in PD patients with more 442 
advanced disease stage and those with dementia. This was later supported by further evidence138, however α-443 
synuclein levels in PD did not differ from atypical parkinsonian disorders but, among FTD patients, patients with 444 
parkinsonism had significantly higher α-synuclein levels than patients without combined parkinsonism.   445 
GFAp—GFAp is a marker of astrogliosis and is increased in the brains of NDDs183. Rapidly elevated blood GFAp 446 
levels are observed in acute structural disintegration of astroglial cells such as intracerebral hemorrhage and 447 
traumatic brain injury184. Subtle changes in serum GFAp can now be observed using the Simoa platform. Serum 448 
GFAp has been shown to be increased in AD, though the levels in PD and bvFTD are normal185. Interestingly, 449 
serum GFAp levels are also increased in LBD and correlate with cognitive decline185. However, there is a 450 
disagreement between serum and CSF, as CSF GFAp levels are increased in most NDDs and only a weak 451 
correlation exists between serum and CSF in the same patients. 452 
TDP-43 - TDP-43 can be measured in CSF but the majority of its expression appears to be blood-derived and its 453 
CSF concentration does not reflect neuropathology in FTD186. Total187 and phosphorylated188 plasma TDP-43 454 
have been reported to be increased in FTD and correlate with more severe TDP-43 pathology in the brain188. In 455 
support of this, a more recent study found higher levels of phosphorylated TDP-43 in both the CSF and plasma of 456 
patients carrying the C9orf72 or GRN mutations than in patients with other types of FTD and healthy controls189. 457 
Increased plasma TDP-43 has also been reported in ALS190. These findings need to be carefully interpreted given 458 
the ubiquitous peripheral expression of TDP-43 (https://www.proteinatlas.org/ENSG00000120948-459 
TARDBP/tissue) and further efforts are needed to separate peripheral TDP-43 from CNS TDP-43. A limitation 460 
of biofluid studies investigating TDP-43 is the use of the commercially available antibodies for TDP-43, which 461 
are restricted to a peptide region or phosphorylation sites of TDP-43 that are not the reported disease-specific 462 
truncated form of TDP-43. 463 
 464 
Non-targeted proteomic studies for non-AD NDD’s 465 
In PD or DLB, most biomarker discovery studies have relied on the proteome analysis of CSF with very little in 466 
plasma or serum. This proteomic profiling has identified changes in proteins such as ApoE, APP, cystatin C191, 467 
Chitinase-3-like protein 1191, Neuronal Pentraxin 1192, Transthyretin191 and Ubiquitin76,191,193. However, there 468 
exists only one study where all three disorders (PD, DLB and AD) were compared together using an isobaric 469 
labelling approach, 72 proteins – including ceruloplasmin and apolipoproteins, were uniquely associated to PD 470 
compared to AD and DLB194. Based on these findings, Zhang et al. validated a panel of eight proteins (tau, Aβ42, 471 
β2-microglobulin, interleukin-8, vitamin D-binding protein, apolipoproteins A and E and BDNF) that were highly 472 
effective at differentiating PD from other conditions195. The LC-MS proteomic analysis of blood samples has 473 
proved challenging although, recent studies successfully highlighted potential PD biomarkers in blood196-198, of 474 
which the most promising and consistent being plasma apolipoprotein A1 (ApoA1). O’Bryant and colleagues, 475 
who used the mesoscale (MSD) panel approach and were able to determine two distinct plasma proteomic profiles. 476 
Firstly, with a diagnostic accuracy of 91%, they were able to distinguish LBD disorders from aged-matched 477 
controls. In contrast, a second protein panel could distinguish between DLB and PD with an accuracy of 92%. 478 
Overall, the proteomic profile of these panels reflected inflammation (i.e, IL5, IL6, Eotaxin), metabolic (i.e, 479 
Adiponectin) and vascular dysfunction (i.e, sVCAM1) in the periphery however; they had little overlap in their 480 
specific composition199. Using a similar approach King and co-workers also demonstrated a strongly increased 481 
inflammatory component in DLB patients, interestingly this was confined to the mild cognitive impairment (MCI) 482 
stage of disease and did not differ from MCI-AD200.  483 
 484 
Exosomes  485 
Exosomes are a discrete population of cell-derived extracellular vesicles of between 30-100nm in size that are 486 
released into the extracellular space upon fusion of multivesicular bodies (MVBs) with the plasma membrane. 487 
Although exosome studies in the context of neurodegeneration are still developing, there has been an enormous 488 
growth over the past decade201. Once primarily thought to be the transporter of unwanted cellular debris it is now 489 
accepted that exosomes transfer biomolecules and pathogenic entities across biological barriers202,203. In recent 490 
times, Goetzl et al. have pioneered the isolation of ‘neuronal specific’ exosomes with the use of ExoQuick (System 491 
Biosciences) isolation coupled with IP with L1CAM (CD171). Their methodology has been used in numerous 492 
studies in AD and PD identifying proteins such as Aβ42204-206, P-tau204,205,207,208, Cathepsin D205,206, REST204-206, 493 
neurogranin204,205,209, DJ-1210 and α-synuclein211. Interestingly, exosomal GAP-43 and synapsin-1 are only altered 494 
in AD and not FTD compared to controls212. The potential of using exosome-based biomarkers as objective 495 
measures of target engagement has been recently demonstrated in neuronally derived exosomes with increased 496 
activity in the AKT pathway after GLP-1 receptor agonist treatment in PD patients213. There has been an 497 
exceptional increase in the number of studies focusing on extracellular vesicles, and growing interest in their 498 
potential as biomarkers214 but challenges remain such as difficulties in reliably and efficiently enriching vesicles 499 
from biofluids and their differentiation. Methods of isolating exosomes rely on physical characteristics, such as 500 
size, flotation density, cell surface markers, and morphology215. These properties are at times used in combination, 501 
and a lack of standards and consensus within the field has led to variations in protocols used by researchers across 502 
laboratories worldwide214.  503 
 504 
RNA biomarkers 505 
Ribonucleic acids (RNA), especially microRNAs (miRNA), remain stable in blood by being protein bound or 506 
encapsulated within exosomes or microvesicles216. They can be detected and measured in all blood fractions using 507 
quantitative polymerase chain reaction (qPCR), northern blotting, oligonucleotide probe florescence assays, gene 508 
expression microarrays, or next-generation RNA-sequencing (RNA-Seq). It has been hypothesised that each NDD 509 
may have its own unique peripheral miRNA signature217,218. Circulating RNA biomarkers for AD have been 510 
investigated219-221, and expression levels of 12 miRNA in blood may reportedly distinguish AD from controls with 511 
93% accuracy222. Systematic studies investigating blood-based RNA biomarkers for non-AD NDD are few. An 512 
oligonucleotide microarray study  has reported identifying 12 differentially expressed mRNA for Huntington’s 513 
disease223, however, the panel showed substantial overlap among the gene expression changes in PD and acute 514 
ischaemic stroke224,225.  515 
Total SNCA mRNA expression in leukocytes did not differ in DLB226, but significantly higher leukocyte 516 
expression levels of an alternatively spliced isoform encoding SNCA-126 in DLB has been reported226. Moreover, 517 
mitochondrial MT-ATP8, MT-CO2, MT-CO3, and MT-ND2 are reportedly downregulated in DLB leukocytes227. 518 
Another study has indicated that people with idiopathic rapid eye movement sleep behaviour disorder and lower 519 
serum levels of miR-19b might have higher risk for developing DLB228. Notwithstanding the increasing interest 520 
on circulating RNA in PD229, systematic research on blood-based RNA biomarkers for PDD remains sparse. 521 
Another small study that investigated blood miRNA profiles of a heterogeneous non-AD NDD group (n=10) 522 
including DLB, vascular dementia, and FTD has found significant downregulation of miR-590-5p and miR-142-523 
5p, and significant upregulation of miR-194-5p, compared with AD230. Furthermore, a study that investigated 524 
brain-enriched plasma miRNA reported that miR-7, miR-9*, let-7e, miR-335-5p, and miR-451 expression levels 525 
could distinguish FTD from controls with 88% accuracy217. The need for further research investigating exosomal 526 
RNA profiles in non-AD dementias cannot be overemphasised.  527 
 528 
Metabolomics 529 
Metabolomics can be defined as “the unbiased analysis of the composition of small molecule metabolites in a 530 
given biological tissue or fluid, under a specific set of environmental conditions”231. The sensitivity of the 531 
metabolome to environmental changes makes it an ideal molecular pool to look for biomarkers but does also make 532 
it susceptible to confounding factors making experimental design imperative. Several studies have used 533 
metabolomics in the search for peripheral biomarkers with some success, with metabolites including sphingolipids 534 
acyl-carnitines and amino acids shown to discriminate AD from controls232-235. However, of more interest, a small 535 
number of studies have looked to discriminate stable and converting MCI. Mapstone et al. reported a panel of 536 
biomarkers that discriminated converting from stable MCI patients with a sensitivity and specificity of up to 537 
90%236. Studies in PD describe 92 biomarker candidates, with three metabolites (5-acetylamino-6-amino-3-538 
methyluracil, alanine and glutamate) validated between studies and three metabolites (indole acetate, theophylline, 539 
uric acid) that have contrary reports. Ten studies have investigated the classification of PD patients from healthy 540 
controls237-240, with the AUC’s ranging from 0.83-0.95. Stoessel et al.241 tested the predictive performance of their 541 
markers using a random forest model, achieving an accuracy of 66%. Interestingly, a cursory review of the 542 
literature showed that 14 candidate PD biomarkers have also been reported as potential biomarkers of AD, which 543 
is a greater overlap than between PD studies, suggesting that these may represent generic makers of NDDs rather 544 
than specific makers of PD or AD. In addition, studies report that plasma levels of uric acid, a product of purine 545 
breakdown, are indeed decreased early in PD patients242, and is associated with poorer attention, executive and 546 
visuospatial functions243. 547 
The kynurenine pathway is modified with reduced levels of kynurenine238 and increased levels of 3-548 
hydroxykynurenine239 (3-HK) and quinolinic acid238, with 3-hydroxykynurenine also increased in the CSF of PD 549 
patients244. However, these shifts are not unique to PD, having also been reported in AD245,246. The kynurenine 550 
pathway is the main route of tryptophan breakdown in mammals, with 3-hydroxykynurenine produced by the 551 
breakdown of kynurenine by kynurenine-3-monoxygenase. Numerous studies have shown that 3-HK is 552 
neurotoxic247,248, through its ability to produce highly reactive free radicals, the increased abundance of 3-HK will 553 
lead to greater production of free radicals and increased neurotoxicity. Quinolinic acid is a downstream product 554 
of 3-HK in the kynurenine pathway produced via anthranilate and 3-hydroxyanthranilate, and has been shown to 555 
be an endogenous excitotoxin249,250 acting specifically via N-methyl-D-aspartate receptors. The methionine cycle 556 
describes metabolic pathways involved in the cytosolic recycling of homocysteine to methionine by means of 557 
remethylation. The maintenance of this cycle, which is dependent on the presence of vitamins B9 and B12, is 558 
often disturbed in PD and other dementias. In both cross-sectional and longitudinal PD cohorts251, higher 559 
homocysteine levels in plasma is associated with cognitive decline. The overlap between the biomarkers reported 560 
for PD and AD combined with the shared pathological features (e.g. via increased 3-HK) suggest the strategies 561 
for future biomarker studies need to identify individuals with specific pathologies rather than specific clinical 562 
phenotypes.  563 
 564 
Future directions 565 
The rapid advancement in highly sensitive quantitative technologies has led to promising developments in blood 566 
biomarker studies in AD. In the same manner, blood-based biomarkers have the potential to improve detection 567 
and diagnosis for non-AD NDD’s by increasing accessibility, acceptability and ease of testing, as well as reducing 568 
costs. However, far fewer blood-based biomarker studies exist for non-AD NDDs. Nonetheless, even at this early 569 
stage, clear examples are emerging of how current blood-based biomarkers can have a potential role in the 570 
differential diagnosis of NDDs. Firstly, despite NFL being a global marker for neurodegeneration, a clear 571 
reduction of NFL in PD compared to AD, FTD and APD has been documented. Furthermore, NFL has the 572 
potential to act as non-specific outcome measure in Phase II clinical trials252,253 and this would also be of huge 573 
benefit in exploring therapeutic interventions for non-AD NDD. Secondly, while plasma Aβ species are being 574 
rigorously investigated by the AD community, plasma Aβ42 could play a role in predicting cognitive decline in 575 
other NDDs with reported amyloid pathology. At this time the plasma Aβ ratio has not been explored in any 576 
capacity outside of AD with very few considerations of Aβ42 in NDD’s. Lastly, early indications demonstrate 577 
that P-tau181 may have huge potential role in classifying AD from NDDs and more specifically the extent of 578 
amyloid and tau pathology. More studies are needed to test the validity of NFL, Aβ and tau species blood 579 
biomarkers in non-AD NDD and like the AD community, these need to be evaluated overtime. This includes 580 
larger sample sizes, including test and validation cohorts that satisfy outlined NPV and PPV18. Finally, 581 
establishing concentration cut-offs for the individual diagnostic accuracy against AD and healthy controls with 582 
age-dependent cut-offs 583 
The AD biomarker field has taken advantage of available methods to detect tangle and plaque pathology to 584 
diagnose AD and preclinical AD pathology in vivo. This has ensured that research cohorts have been well stratified 585 
to maximise the likelihood of establishing a robust blood biomarker reflective of pathology. However, this is been 586 
far more prominent in proteomics studies whereas metabolomic or RNA studies remain largely dependent on 587 
cohorts with purely clinical outcomes. To establish biomarkers for non-AD NDDs, our ability to detect in vivo 588 
measures of other key proteonopathies (i.e. TDP-43 or α-synuclein) has to be improved. This process is likely to 589 
follow a tiered approach where autopsy-confirmed pathologies guide CSF biomarker discovery. This would then 590 
provide candidates for targeted omics or aid the accurate stratification for non-targeted discovery studies to 591 
identify novel blood candidates for NDDs. If identified in the future, these markers can be utilised to track the 592 
development and interaction of co-pathologies over time as well as to characterise clinical syndromes according 593 
to a pathological signature, allowing for personalised treatment and clinical care. 594 
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 628 
Figure Legends  629 
 630 
FIG.1. PET scans from illustrative patients with Alzheimer’s disease (AD), behavioral variant 631 
frontotemporal dementia (bvFTD), corticobasal syndrome (CBS) and progressive supranuclear palsy 632 
(PSP). In the top row, axial slices of [11C]Pittburgh Compound B (PiB) scans reflecting amyloid-β (Aβ)  neuritic 633 
plaque density are displayed for each patient. The scan of the AD patient is “Aβ-positive” (considerable tracer 634 
retention throughout the cortex, especially in contrast to unspecific retention in the white matter [WM]) and “Aβ-635 
negative” in the three non-AD patients (non-specific tracer retention in the WM only). In the middle row, tau PET 636 
imaging using the tracer [18F]flortaucipir (FTP) is shown, which reflects intracellular aggregates of abnormally 637 
phosphorylated tau. Tracer binding in the AD patient is highly elevated in temporo-parietal areas, including the 638 
posterior cingulate and precuneus, as well as dorsal prefrontal cortex. Arrowheads highlight areas of mild to 639 
moderate tracer binding in patients with bvFTD (frontal gray and white matter), CBS (peri-rolandic area, including 640 
white matter), and PSP (frontal regions, globus pallidus/putamen, dentate nucleus). Asterisks indicate brain 641 
regions of unspecific tracer retention (“off-target” binding), including the choroid plexus and extra-axial areas. 642 
Binding patterns found in PSP and CBS in particular overlap with known patterns of off-target binding in the 643 
basal ganglia, midbrain regions, and cerebellum observed in healthy individuals. In the bottom row, glucose 644 
metabolic PET imaging using [18F]FDG (FDG) is shown. Decreased FDG retention overlapped largely in regions 645 
of increased FTP across all patients. All scans courtesy of Dr Rabinovici / Dr La Joie, University of California, 646 
San Francisco, Memory and Aging Center. PiB PET scans were acquired 50-70 min post tracer injection, and 647 
standardized uptake values ratio (SUVR) were created using a cerebellar reference region; FTP scans were 648 
acquired at 80-100 min post tracer injection and SUVR created using an inferior cerebellar reference region; FDG 649 
scans were acquired at 30-60 min post tracer injection and SUVR created using the pons as reference region. 650 
MMSE, Mini Mental State Examination.  651 
 652 
FIG. 2. Current strategies for blood biomarker discovery in neurodegenerative disorder research.  653 
Abbreviations. ELISA, enzyme-linked immunosorbent assay; ECL, electrochemiluminescence; MSD, Meso 654 















Table 1. Clinical, pathologic and biomarker features of the most common neurodegenerative disorders 670 
NDD  Proteinopathy 
Main regional 
involvement 
Clinical characteristic Biomarkers 
AD Aβ, tau 
medial temporal 
lobe, parietal lobe 
Memory, language, 
apraxia, agnosia 
sMRI, FDG-PET, Aβ PET, 
tau-PET, CSF Aβ, CSF T-tau, 
CSF P-tau  
FTD TDP-43, tau, FET 
frontal and anterior 
temporal lobes 
Behavior, language/speech sMRI, FDG-PET  









DATscan, MIBG, PSG, EEG, 
MRI 



























Table 2. A summary of fluid biomarkers for Alzheimer’s disease 698 
Biomarker Fluid 
matrix 
Observation in AD Interpretation / application  
Aβ42 
CSF 
Decreased Aβ42 in AD and 
prodromal AD (sensitivity >90%) 
Reflects cerebral Aβ deposition.  
Diagnostic biomarker with two fully 
validated mass spectrometry Reference 
Measurement Procedures (RMP) approved   
Blood 
(plasma) 
IP-MS show decreased plasma Aβ42 
in AD. Plasma Aβ42 levels show a 
weak–moderate concordance with 
amyloid PET. 
Reflects cerebral Aβ deposition but 
influenced by peripheral expression. 
Candidate screening tool 
Aβ42/Aβ40 
CSF 
Low Aβ42/Aβ40 ratio is found in 
AD and prodromal AD. Increased 
sensitivity and specificity than Aβ42 
alone. 
The Aβ42/Aβ40 ratio is thought to 
compensate for between-individual 




Simoa and IP-MS methods show 
reduced plasma Aβ42/40 ratio in 
AD dementia and prodromal AD. 
Plasma Aβ42/40 ratio shows 
moderate-high concordance with 
amyloid PET outcomes 
Aβ42/Aβ40 ratio may reflect mechanisms 
associated with cerebral amyloidosis 
Candidate screening tool 
T-tau 
CSF 
High T-tau is found in AD and 
prodromal AD (sensitivity >90%) 





Weak-moderate increases in AD and 
prodromal AD 
Influenced by peripheral expression 
Unlikely to have a biomarker role in AD 
P-tau 
CSF 
High P-tau is found in AD and 
prodromal AD (sensitivity >90%). 
High P-tau reflects phosphorylation state 
of tau and thus probably tau pathology in 





Increased P-tau is seemingly 
specific to Aβ positive AD’s. 
Concordance with amyloid PET and 
tau PET (MSD assay) 
Candidate diagnostic and screening 
biomarker 
Neurogranin CSF 
High neurogranin is found in AD 
and prodromal AD 
Reflects synaptic dysfunction or 
degeneration 





Increased in AD, familial AD and 
prodromal AD 
High plasma NFL is a general biomarker 
for neurodegeneration, and not specific for 
AD 


























IMR plasma ↑  ↑ 
↑ (NB: highest in FTD 
without parkinsonism) 
↑ CBD, ↑ PSP, 
↑ MSA 
Simoa plasma     ↑ CJD 
ELISA plasma     ↑ CJD 
P-tau181 
IMR plasma ↑  ↑ ↑ 




plasma    ↔ 
↔ CBD, ↔ 
PSP, ↔ MSA 




↔ CBD, ↔ 




↔ ↑ ↑ ↑ 
↑ CJD, ↑ ALS 
pNFH Simoa serum    ↑ ↑ ALS 
α-syn IMR plasma ↑ ↑ ↑ ↑ (NB: not FTD without 
parkinsonism) 
↑ CBD, ↑ PSP, 
↑ MSA 
FABP ELISA serum ↑  ↑  ↑ CJD 
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